Ian C Marschner (I C Marschner, Ian Marschner)

ORCID

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 15

Top Venues

Statistics in medicine

Statistical methods in medical research

JCO precision oncology

Biometrical journal. Biometrische Zeitschrift

NHMRC Clinical Trials Centre, University of Sydney

This page only lists publications with an associated author ORCID identifier.

Affiliation History

NHMRC Clinical Trials Centre, University of Sydney

Australia

Professor of Biostatistics

Publications

Rachel G Woodford, Deborah Di-Xin Zhou, Peey Sei Kok, Sally J Lord, Michael L Friedlander, Ian C Marschner, R John Simes, Chee Khoon Lee
Validity and Efficiency of Progression-Free Survival-2 as a Surrogate End Point for Overall Survival in Advanced Cancer Randomized Trials. JCO precision oncology 8 (2024)
Ian C Marschner
Confidence distributions for treatment effects in clinical trials: Posteriors without priors. Statistics in medicine 43 (6) (2024)
Ian C Marschner
Confidence distributions for treatment effects in clinical trials: Posteriors without priors. Statistics in medicine (2024)
Ian C Marschner
Confidence distributions for treatment effects in clinical trials: Posteriors without priors. Statistics in medicine 43 (6) (2024)
Ian C Marschner, I Manjula Schou
Analysis of Nonconcurrent Controls in Adaptive Platform Trials: Separating Randomized and Nonrandomized Information. Biometrical journal. Biometrische Zeitschrift 66 (6) (2024)
Rachel G Woodford, Deborah Di-Xin Zhou, Peey Sei Kok, Sally J Lord, Michael L Friedlander, Ian C Marschner, R John Simes, Chee Khoon Lee
Validity and Efficiency of Progression-Free Survival-2 as a Surrogate End Point for Overall Survival in Advanced Cancer Randomized Trials. JCO precision oncology 8 (2024)
Anne Lyngholm Sørensen, Ian C Marschner
Linear mixed models for investigating effect modification in subgroup meta-analysis. Statistical methods in medical research (2023)
Ian C Marschner, Mark Jones, James A Totterdell, Robert K Mahar, Thomas L Snelling, Steven Y C Tong, null null
Transparent reporting of adaptive clinical trials using concurrently randomised cohorts. BMJ medicine 2 (1) (2023)
Ian C Marschner, Manjula Schou, Andrew J Martin
Estimation of the treatment effect following a clinical trial that stopped early for benefit. Statistical methods in medical research 31 (12) (2022)
Ian C Marschner, I Manjula Schou
Analysis of adaptive platform trials using a network approach. Clinical trials (London, England) 19 (5) (2022)
Rachel G Woodford, Deborah Di-Xin Zhou, Peey Sei Kok, Sarah Sally J Lord, Michael L Friedlander, Ian C Marschner, R John Simes, Chee Khoon Lee
The validity of progression-free survival 2 as a surrogate trial end point for overall survival. Cancer 128 (7) (2022)
Rachel G Woodford, Deborah Di-Xin Zhou, Sarah Sally J Lord, Ian C Marschner, Wendy Anne Cooper, Craig R Lewis, Thomas John, James Chih-Hsin Yang, Chee Khoon Lee
PD-L1 expression as a prognostic marker in patients treated with chemotherapy for metastatic non-small-cell lung cancer. Future oncology (London, England) 18 (14) (2022)
Ian C Marschner, Lisa M Askie, I Manjula Schou
Sensitivity analyses assessing the impact of early stopping on systematic reviews: Recommendations for interpreting guidelines. Research synthesis methods 11 (2) (2020)
Ian C Marschner
Back-projection of COVID-19 diagnosis counts to assess infection incidence and control measures: analysis of Australian data. Epidemiology and infection 148 (2020)
Ian C Marschner, I Manjula Schou
Underestimation of treatment effects in sequentially monitored clinical trials that did not stop early for benefit. Statistical methods in medical research 28 (10-11) (2018)

Ian C Marschner.css-eqlu8i{font-size:small;padding-left:4px;} (I C Marschner, Ian Marschner)

Publication Activity (10 Years)

Top Topics

Top Venues

Ian C Marschner (I C Marschner, Ian Marschner)